11 results about "Progenitor" patented technology

The present application relates to a kind of sgRNA targeting Plagl1 gene DMR, epigenetic editing system and its application.Specifically, the present application provides sgRNA targeting Plagl1 gene differential methylation region, which forms epigenetic editing system with dCas9-Tet1-CD fusion protein.The system is loaded in injectable type light-cured silk fibroin hydrogel, the expression of Plagl1 gene in periosteum stem / progenitor cells is accurately activated by targeted demethylation modification, thereby promoting osteogenic differentiation.The present application combines epigenetic regulation with biomaterial delivery, and provides a safe, efficient new strategy for jaw bone defect regeneration and repair.

This provides a molecular diagnostic tool useful for the efficient and accurate characterization of the discriminative and functional properties of iPSC-derived dopaminergic neurons. [Solution] A computer-based method for identifying determined dopaminergic progenitor cells within an in vitro population of neural progenitor cells is provided, comprising: receiving a test dataset containing data such as gene expression profile information relating to an in vitro population of neural progenitor cells; querying a gene expression reference database and comparing the test dataset with the gene expression reference database, wherein the gene expression reference database contains gene expression profile information of the desired determined dopaminergic progenitor cells; and outputting a computer-calculated label classification that includes an indication of whether or not the in vitro population of neural progenitor cells contains the determined dopaminergic progenitor cells.

The method for producing a cell aggregate including glial progenitor cells according to the present invention comprises:(1) a step of subjecting pluripotent stem cells to suspension culture in an embryoid-body-forming culture medium containing one or more SMAD signaling inhibitors and one or more Wnt signaling activators in the absence of feeder cells for 5 days to 10 days, to form a cell aggregate;(2) a step of subjecting the cell aggregate obtained in (1) to suspension culture in an embryoid-body-forming culture medium containing retinoic acid;(3) a step of subjecting the cell aggregate obtained in (2) to suspension culture in an embryoid-body-forming culture medium or neuron-and-glia-proliferating culture medium containing retinoic acid and one or more SHH signaling activators; and(4) a step of subjecting the cell aggregate obtained in (3) to suspension culture in a neuron-and-glia-proliferating culture medium containing no retinoic acid and one or more SHH signaling activators.

This disclosure relates to a method for producing induced midbrain dopaminergic progenitor cells (imDAPs) that can provide high imDAP cell differentiation efficiency. This disclosure also provides a substantially homogeneous imDAP cell population.

This invention provides the application of T-5224 in the expansion and / or functional enhancement of human circulating hematopoietic stem / progenitor cells, relating to the fields of stem cell biology and regenerative medicine. It is the first time T-5224 has been applied to the expansion of cHSPCs, opening up a new pathway to improve stem cell culture efficacy by regulating downstream transcriptional hubs of inflammatory / stress signals. Accompanied by the upregulation of HOXB4 gene expression, it significantly improves LIN... ‑ CD45RA ‑ CD34 + CD38 low / ‑ The cell expansion factor, maintaining cell stemness and regeneration capacity, provides a new approach to solving the technical problem of the difficulty in rapidly expanding human circulating hematopoietic stem / progenitor cells in in vitro culture while maintaining cell stemness and regeneration potential.

A health care device and an use thereof are configured to transmit a low frequency wave to a spine or navel to increase the number of endothelial progenitor cells (EPC) and to reduce the number of the circulating endothelial cells (CEC), which may reduce the risk of cardiovascular-related adverse diseases. The health care device includes a box body, a power supply, a speed controller, a rotating mechanism, a linkage mechanism, a knocker and a conical table. The power supply is electrically connected to the speed controller to output electricity to the speed controller. The speed controller is electrically connected to the rotating mechanism and controls the rotating mechanism to rotate at a predetermined speed. The rotating mechanism is connected to the knocker to drive the knocker to knock a flat surface of the conical table. The knocker generates the low frequency wave with a predetermined frequency.

Methods, compositions and cells are provided that identify and isolate a population of adult non-embryonic progenitor cells having multilineage potential, physical diameters of about 2 μm to about 8 μm in size or about 4 μm to about 6 μm, and expressing at least one of the stem cell associated genes among Oct-4, KLF-4, Nanog, Sox-2, Rex-1, GDF-3 or Stella. Methods are also provided that identify and isolate populations, which are subsets or subpopulations of progenitor adult stem cells within the population of the adult stem cells which is a heterogeneous population, the methods including contacting the adult stem cells with a ligand specific for at least one of: CD99, tetraspan, ICAM4, full-length MUC1, and truncated MUC1 receptor, in which a presence of a surface protein on the cells that bind to the ligand identifies the population which is the subset of the differentiated progenitor adult stem cells.

The present disclosure, in various aspects and embodiments, provides methods for detecting specific hematopoietic lineages derived from HSPCs. Methods may involve culturing HSPCs in a culture medium for a sufficient time to obtain an output population of cells that includes a lymphoid lineage cell(s), and one or both of a myeloid lineage cell(s) and an erythroid lineage cell(s). Methods of simultaneously obtaining lymphoid, myeloid and erythroid lineage cells from HSPCs obtained from different sources are also described. Methods of the present disclosure may reliably detect multilineage differentiation potential of HSPCs in vitro.

This invention provides the application of JSH-23 in the expansion and / or functional enhancement of human circulating hematopoietic stem / progenitor cells, relating to the fields of stem cell biology and regenerative medicine. The small molecule compound JSH-23 effectively reduces the protein level of phosphorylated NF-κB p65 (Ser536) in cultured cells, accompanied by upregulation of HOXB4 gene expression, and significantly improves LIN. ‑ CD45RA ‑ CD34 + CD38 low / ‑ The cell expansion factor, maintaining cell stemness and regeneration capacity, provides a new approach to solving the technical problem of the difficulty in rapidly expanding human circulating hematopoietic stem / progenitor cells in in vitro culture while maintaining cell stemness and regeneration potential.

The invention discloses a method for enhancing hematopoietic stem progenitor cell functions and application thereof, and belongs to the technical field of biological medicine. According to the method, the hematopoietic stem progenitor cells are treated through non-thermal radio frequency radiation with specific parameters, the in-vitro clone formation capacity, the in-vivo hematopoietic reconstruction function and the ionizing radiation damage resistance of the hematopoietic stem progenitor cells can be enhanced, and the method can be applied to the scenes of hematopoietic stem cell transplantation curative effect improvement, radiation-induced hematopoietic damage treatment and the like.

This disclosure provides a method and kit for analyzing compositions of human floorplate mesencephalic dopaminergic (mesDA) progenitor cells that are obtained, for example, by differentiating embryonic stem cells. The mesDA progenitors are characterized using the positive markers FOXA2. OTX2, and optionally NKX2. 1. in combination with the negative markers OCT3 / 4, and optionally PAX6, and SOXI. Cells with an appropriate protein expression profile have therapeutic potential for restoring the function of dopaminergic neurons in conditions such as Parkinson's Disease.